Vasopressin trisulphide: Synthesis, NRM study and affinity studies with V1 and V2 subtypes receptors

Bioorganic and Medicinal Chemistry Letters

Volumn 7, Issue 6, 1997, Pages 719-724

  Moutiez, Mireille ^a,b   Lippens, Guy ^a   Sergheraert, Christian ^a   Tartar, André ^a  

^a CNRS   (France)

^b CEA SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

UNCLASSIFIED DRUG; VASOPRESSIN; VASOPRESSIN DERIVATIVE; VASOPRESSIN TRISULFIDE; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ANIMAL CELL; ARTICLE; DRUG ACTIVITY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RAT; RECEPTOR AFFINITY; SWINE;

EID: 0031576879     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(97)00050-4     Document Type: Article

References (18)

1. 1. Zein, N.; Sihna, A.M.; McGahren, W.J.;Ellestad, G.A. Science, 1988, 240, 1198.
2. 2. Golik, J.; Clardy, J.; Dubay, G.; Groenewold, G.; Hawaguchi, H.; Konishi, M.; Krishman, B.; Okhuma, H.; Saitoh, K.; Doyke, T.W. J. Am. Chem. Soc., 1987, 109, 3461.
3. 3. Litaudon, M.; Guyot, M. Tetraedron Lett., 1991, 32, 911.
4. 4. Parmentier, B.; Moutiez, M.; Tartar, A.; Sergheraert, C. Tetraedron Lett., 1994, 35, 3531.
5. 5. Jespersen, A.M.; Christensen, T.; Klausen, N.K.; Nielsen, P.F., Sorensen, H.H. Eur. J. Biochem., 1994, 219, 365.
6. 6. a/ Moutiez, M.; Aumercier, M.; Teissier, E.; Parmentier, B.; Tartar, A.; Sergheraert, C. Biochem. Biophys. Res. Comm., 1994, 202, 1380 -
7. b/ Moutiez, M.; Aumercier, M.; Parmentier, B.; Tartar, A.; Sergheraert, C. Biochim. Biophys. Acta, 1995, 1245, 161.
8. 7. Rudinger, J.; Jost, K. Experientia. 1964, 10, 571.
9. 8. Hase, S.; Morikawa, T.; Sakakibara, S. Experientia. 1969, 25, 1240.
10. 9. Mouillac, B.; Chini, B.; Balestre, M.N.; Elands, J.; Trumpp-Kallmeyer, S.; Hoflack, J.; Hibert, M.; Jard, S.. Barberis, C. J. Biol. Chem., 1995, 270, 25771.
11. 10. Lundin, R.H.L.; Noren, B.E.; Edlun, P.O. Tetraedron Lett. 1994, 35, 6339.
12. 11. Dihydrovasopressin was prepared by solid phase peptide synthesis on a Applied Biosystems 430A synthetiser, using the Boc strategy. mBHA resin (0.75 mmol/g) was from ABI. Amino acids protecting groups were as follows: tosyl (Arg), 4-MeBzl (Cys), Brz (Tyr). Cleavage of the peptide from the resin and simultaneous deprotection of the side chains was achieved by treatment with anhydrous HF (10 ml/g of resin bound peptide) containing p-cresol (0.1 g/ml of HF) for 60 min at 0°C. The crude peptide was lyophilised and purified by HPLC in conditions described in reference 10.
13. 2O 60%, TFA 0.05%). Preparative HPLC: 0 to 15% B (10 min), 15% to 60% B (3h), 60 % to 100% B (20 min). Analytical HPLC: linear gradient, 0 to 100% B (30 min)
14. 13. Thibonnier, M.; Bayer, A.L.; Simonson, M.S.; Kesler, M. Endocrinology, 1991, 129, 2845.
15. 14. Lutz, W.; Londowski, J.M.; Sanders, M.; Salisbury, J.; Kumar, R.J. J. Biol. Chem. 1992, 267, 1109.
16. 15. Schmidt, J.M.; Ohlenschläger, O., Rüterjans, H.Z., Grzonka, Z.; Kojro, E.; Pavo, I.; Farhenholz, F Eur. J. Biochem., 1991, 201, 355.
17. 16. Wood, S.P.; Tickle, I.J., Treharne, A.M.; Pitts, J.E.; Mascarenhas, Y.; Li, J.Y., Husain, J.; Cooper, S.; Blundell, T.L.. Hruby, V.J.; Buku, A.; Fishman, A.J.; Wyssbrod, H.R. Science, 1986, 232, 633.
18. 17. Weisshoff, H.; Frost, K.; Brandt, W.; Henklein, P.; Mügge, C.; Frömmel, C. FEBS Letters, 1995, 372, 203.